HomeCompareINPX vs ABBV

INPX vs ABBV: Dividend Comparison 2026

INPX yields 3795.07% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INPX wins by $4322908420209.51M in total portfolio value
10 years
INPX
INPX
● Live price
3795.07%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4322908420209.61M
Annual income
$4,109,875,340,592,546,300.00
Full INPX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — INPX vs ABBV

📍 INPX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINPXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INPX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INPX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INPX
Annual income on $10K today (after 15% tax)
$322,580.65/yr
After 10yr DRIP, annual income (after tax)
$3,493,394,039,503,664,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, INPX beats the other by $3,493,394,039,503,643,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INPX + ABBV for your $10,000?

INPX: 50%ABBV: 50%
100% ABBV50/50100% INPX
Portfolio after 10yr
$2161454210104.86M
Annual income
$2,054,937,670,296,285,400.00/yr
Blended yield
95.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

INPX
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
0.0
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INPX buys
0
ABBV buys
0
No recent congressional trades found for INPX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINPXABBV
Forward yield3795.07%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4322908420209.61M$102.3K
Annual income after 10y$4,109,875,340,592,546,300.00$24,771.77
Total dividends collected$4308344536195.87M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: INPX vs ABBV ($10,000, DRIP)

YearINPX PortfolioINPX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$390,207$379,506.64$11,550$430.00+$378.7KINPX
2$14,257,335$13,839,814.20$13,472$627.96+$14.24MINPX
3$487,851,509$472,596,159.98$15,906$926.08+$487.84MINPX
4$15,635,175,719$15,113,174,604.74$19,071$1,382.55+$15635.16MINPX
5$469,405,186,241$452,675,548,221.17$23,302$2,095.81+$469405.16MINPX
6$13,203,569,445,578$12,701,305,896,300.34$29,150$3,237.93+$13203569.42MINPX
7$348,021,399,066,998$333,893,579,760,230.00$37,536$5,121.41+$348021399.03MINPX
8$8,597,439,308,359,841$8,225,056,411,358,154.00$50,079$8,338.38+$8597439308.31MINPX
9$199,096,336,090,714,370$189,897,076,030,769,340.00$69,753$14,065.80+$199096336090.64MINPX
10$4,322,908,420,209,610,000$4,109,875,340,592,546,300.00$102,337$24,771.77+$4322908420209.51MINPX

INPX vs ABBV: Complete Analysis 2026

INPXStock

Inpixon, together with its subsidiaries, provides solutions and technologies worldwide. The company operated through three segments: Indoor Intelligence, Saves, and Shoom. The Indoor Intelligence segment offers smart office app provide a frictionless work environment; executive briefing centers, an omni-channel software platform provides a virtual briefing platform allowing organizations to offer a personalized experience for in-office, remote, and hybrid meetings; events, offers a mobile first and virtual event platform to connect remote and in person audiences in a fully branded, end to end event experience; inpixon mapping solution which provides users with the tools to add intelligence to complex indoor spaces; augmented reality and 3D allow businesses to scan a space and attach AR content persistently to any position; analytics and insights, a cloud-based analytics platform allows data from multiple sensors and data sources to be visualized for action by the operator; and on-device positioning solution enables a smartphone's precise location to be displayed to a user in a mobile app. This segment also provides Internet of Things (IoT) software-as-a-service platform, IoT devices, sensors and tags, video integration, security, and transceiver/modules. The Shoom segment offers digital solutions or cloud-based applications and analytics for the media and publishing industry, including eTearsheets and eInvoice. The SAVES provides a set of data analytics and statistical visualization software solutions for engineers and scientists, as well as data analytics and statistical visualization tools which comprise SigmaPlot, SigmaStat, SYSTAT, PeakFit, TableCurve 2D, TableCurve 3D, SigmaScan and MYSTAT. The company was formerly known as Sysorex Global and changed its name to Inpixon in March 2017. Inpixon is headquartered in Palo Alto, California.

Full INPX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this INPX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INPX vs SCHDINPX vs JEPIINPX vs OINPX vs KOINPX vs MAININPX vs JNJINPX vs MRKINPX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.